Follow us on Twitter
twitter icon@FreshPatents


Leukemia patents

      

This page is updated frequently with new Leukemia-related patent applications.




 Epigenetic stem cell commitment-associated signature patent thumbnailEpigenetic stem cell commitment-associated signature
Methods for determining the prognosis of a subject having acute myeloid leukemia (aml) as well as methods of treating aml subjects depending on prognosis.. .
Albert Einstein College Of Medicine, Inc.


 Compositions and methods for treatment of hematological malignancies patent thumbnailCompositions and methods for treatment of hematological malignancies
Use of a chimeric protein selected from the group consisting of ctla4-fasl and cd40-fasl proteins for treatment of lymphoma and/or a multiple myeloma and/or a leukemia as described herein, and pharmaceutical compositions and methods of treatment thereof.. .
Hadasit Medical Research Service And Development Co. Ltd.


 Quantification  expression level of wt1 mrna patent thumbnailQuantification expression level of wt1 mrna
A method for quantifying the expression level of human wt1 mrna conveniently, in a short period of time, and with high sensitivity is provided. The method can be used for diagnosing cancer, such as leukemia and solid cancer, or for determining when to perform bone marrow transplantation.
Otsuka Pharmaceutical Co., Ltd.


 Baff selective binding compounds and related methods patent thumbnailBaff selective binding compounds and related methods
The present invention relates to peptide antagonists that bind with high specificity and affinity to b-lymphocyte stimulator (“baff”), thereby antagonizing baff receptor (“baff-r”) signaling. The invention more specifically relates to vnar single chain antibodies derived from nurse shark that bind to baff, baff antagonist compounds and compositions comprising a baff specific vnar binding moiety, methods for preparing them, diagnostic and therapeutic methods of use relating to in vitro or in vivo b cell depletion, e.g., to treat and/or prevent a pathological condition, disorder or disease in which it is beneficial to kill or deplete b cells, such as in autoimmune diseases including systemic lupus erythematosus (sle), rheumatoid arthritis (ra) or multiple sclerosis (ms), and in certain hematological cancers, including lymphomas, leukemias and myelomas..
Ossianix, Inc.


 Heterocyclic compounds and their uses patent thumbnailHeterocyclic compounds and their uses
Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (sle), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, the present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110δ activity, including but not restricted to leukemias, such as acute myeloid leukaemia (aml) myelo-dysplastic syndrome (mds) myelo-proliferative diseases (mpd) chronic myeloid leukemia (cml) t-cell acute lymphoblastic leukaemia (t-all) b-cell acute lymphoblastic leukaemia (b-all) non hodgkins lymphoma (nhl) b-cell lymphoma and solid tumors, such as breast cancer.. .
Amgen Inc.


 Anti-lag-3 antibodies to treat hematological malignancies patent thumbnailAnti-lag-3 antibodies to treat hematological malignancies
Provided are methods for clinical treatment of hematological malignancies, such as relapsed or refractory chronic lymphocytic leukemia or lymphoma using an anti-lag-3 antibody. Particular malignancies include, e.g., chronic lymphocytic leukemia (cll), hodgkin lymphoma (hl), or non-hodgkin lymphoma (nhl)..
Bristol-myers Squibb Company


 5'-substituted nucleoside compounds patent thumbnail5'-substituted nucleoside compounds
The present invention relates to novel 5′-substituted nucleoside compounds, pharmaceutical compositions comprising the compounds, and methods of using the compounds to treat cancer, more particularly for the treatment of cancer, in particular glioblastomas, melanoma, sarcomas, gastric cancer, pancreatic cancer, cholangiocarcinoma, bladder cancer, breast cancer, non-small cell lung cancer, leukemias including acute myeloid leukemia, and lymphomas.. .
Eli Lilly And Company


 Non-invasive diagnostic agents of cancer and methods of diagnosing cancer, especially leukemia and lymphoma patent thumbnailNon-invasive diagnostic agents of cancer and methods of diagnosing cancer, especially leukemia and lymphoma
The present invention is directed to novel non-invasive diagnostic tools to image cancers, especially, leukemia and non-hodgkin's lymphomas (nhl) with minimal toxicity in vivo. The present invention represents a clear advance in the art which presently relies on tissue biopsy for diagnoses of these cancers.
Stc.unm


 Substituted aminopyrimidine compounds and methods of use patent thumbnailSubstituted aminopyrimidine compounds and methods of use
The invention relates to the preparation and use of new aminopyrimidine derivatives as drug candidates in free form or in pharmaceutically acceptable salt form and formulations thereof for the modulation of a disorder or disease which is mediated by the activity of the pi3k enzymes. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of disorders or diseases, such as disorders of immunity and inflammation in which pi3k enzymes play a role in leukocyte function, and hyperproliferative disorders associated with pi3k activity, including but not restricted to leukemias and solid tumors, in mammals, especially humans..
Sunshine Lake Pharma Co., Ltd.


 Substituted aminopyrimidine compounds and methods of use patent thumbnailSubstituted aminopyrimidine compounds and methods of use
The invention relates to the preparation and use of new aminopyrimidine derivatives as drug candidates in free form or in pharmaceutically acceptable salt form and formulations thereof for the modulation of a disorder or disease which is mediated by the activity of the pi3k enzymes. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of disorders or diseases, such as disorders of immunity and inflammation in which pi3k enzymes play a role in leukocyte function, and hyperproliferative disorders associated with pi3k activity, including but not restricted to leukemias and solid tumors, in mammals, especially humans..
Calitor Sciences, Llc


Combination of epigenetic factors and bispecific compounds targeting cd33 and cd3 in the treatment of myeloid leukemia

The present invention provides a combination epigenetic factors and bispecific compounds targeting cd33 and cd3 in the treatment of myeloid leukemia, wherein the epigenetic factor is selected from the group consisting of histone deacetylase (hdac) inhibitors, dna methyltransferase (dnmt) i inhibitors, hydroxyurea, granulocyte-colony stimulating factor (g-csf), histone demethylase inhibitors and atra (all trans-retinoic acid). Accordingly, the invention provides a pharmaceutical composition comprising a cd33 targeting compound and at least one epigenetic factor and an epigenetic factor for use in the amelioration and/or treatment of a myeloid leukemia, wherein the epigenetic factor increases the responsiveness of a patient to a cd33 targeting compound.
Amgen Research (munich) Gmbh

Combination of an arsenic compound and at least one retinoid for treating acute myeloid leukemia

The present invention relates to methods and pharmaceutical compositions for the treatment of acute myeloid leukemia. In particular, the present invention relates to a method for treating npm-1-driven acute myeloid leukemia (aml) in a subject in need thereof comprising administering the subject with a therapeutically effective amount of at least one arsenic compound and with a therapeutically effective amount of at least one retinoid..
Assistance Publique -hÔpitaux De Paris (aphp)

Methods for determining drug efficacy for the treatment of diffuse large b-cell lymphoma, multiple myeloma, and myeloid cancers

Provided herein, in some embodiments, are methods of using certain cereblon-associated proteins, such as aiolos, ikaros, interferon (ifn), and ifn pathway proteins, casein kinase 1, alpha 1 (csnk1a1), and zfp9, as biomarkers for use in predicting and monitoring clinical sensitivity and therapeutic response to certain compounds in patients having various diseases and disorders, such as cancers (e.g., diffuse large b-cell lymphoma (dlbcl), multiple myeloma (mm), myelodysplasia syndromes (mds) and acute myeloid leukemia (aml)) and ifn-associated disorders. Also provided herein, in certain embodiments, are methods of determining the efficacy of an immunomodulatory compound..
Celgene Corporation

Diagnosis and treatment of cancer using anti-itm2a antibody

Disclosed is a monoclonal antibody binding to an itm2a protein. This antibody is useful in the diagnosis, prevention, and treatment of cancer such as ewing's sarcoma, t cell leukemia, t cell lymphoma, acute myeloid leukemia, b cell tumor, and multiple myeloma.
Chugai Seiyaku Kabushiki Kaisha

Compounds as tnik, ikkepsilon and tbk1 inhibitors and pharmaceutical composition comprising same

Provided is a compound of formula (i) as a tnik (traf2- and nck-interacting kinase), ikkε (i-kappa-b kinase epsilon) and tbk1 (tank-binding kinase 1) inhibitor; the compound according to the present invention effectively inhibits tnik, ikkε and tbk1, and thus is useful not only as an anticancer agent for the treatment of various cancers including colorectal cancer, breast cancer, cns cancer, colon cancer, non-small cell lung cancer, kidney cancer, prostate cancer, ovarian cancer, uterus cancer, stomach cancer, liver cancer, skin cancer, lung cancer, brain cancer, bladder cancer, esophageal cancer, pancreatic cancer, thyroid cancer, head and neck cancer, squamous cell carcinoma, osteosarcoma, b-cell or t-cell lymphoma, acute or chronic leukemia and multiple myeloma, but as a therapeutic agent for chronic inflammation.. .
Green Cross Corporation

Leukemic stem cell markers

The present invention relates to a method for identifying leukemic stem cells (lsc), based on measurement of the presence of a specific set of markers. The invention further relates to a container for use in performing the method.
Stichting Vu-vumc

Cd38 as a prognostic indicator in b cell chronic lymphocytic leukemia

The subject invention discloses a method for determining the prognosis and probable clinical course of a subject diagnosed with b-cll. Specifically, the invention involves comparing cd38 expression in a biological sample from the subject containing b-cll cells to a baseline level of cd38 expression, wherein an elevated level of cd38 expression in relation to the baseline level of cd38 expression may indicate poor prognosis or aggressive course of disease in the subject.
The Feinstein Institute For Medical Research

Antibodies targeting b-cell receptor complex membrane bound igm and uses thereof

The present invention relates to antibodies targeting the membrane bound igm (migm) of the b-cell receptor complex found in b-cell lymphomas and leukemias and uses thereof. Another aspect of the present invention is the use of anti-b-cell migm antibodies in the treatment of be-cell malignancies, including b-cell lymphomas and leukemias..
Welt Bio-molecular Pharmaceutical, Llc

Antibodies for diagnosis of acute myeloid leukemia

A polypeptide in particular an antibody or antibody fragment is disclosed wherein the polypeptide is corresponding to certain complementarity determining regions cdr1, cdr2 and cdr3 of a heavy chain vh and a light chain vl of an antibody as well as a compound comprising the polypeptide, its use as diagnostic agent for acute myeloid leukemia subtype m2 and a kit comprising the compound.. .
Fraunhofer-gesellschaft Zur FÖrderung Der Angewandten Forschung E.v.

Method of treatment of philadelphia chromosome positive leukemia

The invention provides a method for the treatment of ph+ leukemia in a patient comprising administering to the patient (i) a bcr-abl tyrosine kinase inhibitor, and (ii) an agent which selectively binds to a cell surface receptor expressed on ph+ leukemic stem cells. The invention further provides for the use of (i) and (ii) in, or in the manufacture of a medicament for, the treatment of ph+ leukemia in a patient; and a composition for the treatment of ph+ leukemia in a patient comprising (i) and (ii); and kits comprising (i) and (ii).
Csl Limited

Combination therapy for treating adult patients with relapsed/refractory cd22+ b-cell acute lymphoblastic leukemia

The present invention relates to use of combination therapy with an anti-cd22 antibody, such as epratuzumab or hrfb4, and another therapeutic agent for treatment of relapsed/refractory acute lymphoblastic leukemia (all). Preferably the therapeutic agent is a chemotherapeutic agent, more preferably vincristine and/or dexamethasone.
Chu De Nantes

Compounds and methods for the treatment of cancer

The present invention relates generally to the field of anti-cancer therapy. More particularly, it provides novel crystalline forms of organic arsenic compounds and methods for their use in treating cancers such as leukemia and solid tumors.
Solasia Pharma K.k.

Crystalline forms of n-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl -2-thienyl)-1-phthalazinamine salts and uses thereof

The present invention relates to crystalline forms and co-crystal forms of pharmaceutically acceptable salts of the compound, n-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine (amg 900, and pharmaceutical compositions comprising said crystalline and co-crystal forms thereof. The invention further provides uses of the crystalline forms and compositions, to treat cancer, including various types of solid tumors and hematologic cancer including myeloma and leukemia..
Amgen Inc.

Aryl naphthyl methanone oxime(s) and process for preparation thereof

The present invention relates to substituted aryl naphthyl methanone oximes of general formula (i), their process for preparation and their derivatives, salts, pharmaceutical composition thereof and their use in treatment of chronic myelogenous leukemia, acute myelogenous leukemia, lymphoma, multiple myeloma, solid tumor forming cell- lines including such as breast cancer, endometrial cancer colon cancer, prostate cancer and killing of drug resistant cancer stem cells, as subject in need thereof.. .
Council Of Scientific & Industrial Research

Novel combination treatment for acute myeloid leukemia (aml)

The present invention relates to a pharmaceutical product comprising a) as a first component an inhibitor of the mdm2-p53 interaction; and b) as a second component cytarabine; as a combined preparation for the sequential or simultaneous use in the treatment of cancer, particularly aml.. .
Hoffmann-la Roche Inc.

Methods for the detection and treatment of leukemias that are responsive to dot1l inhibition

Disclosed are: (i) methods for identifying leukemia patients who (or leukemia cells that) do not exhibit an mll-translocation, rearrangement or mll-partial tandem duplication but who are nonetheless susceptible to treatment with dot1l inhibitors; and (ii) methods for treating leukemia patients who (or inhibiting proliferation or inducing apoptosis of leukemia cells that) do not exhibit an mll-translocation, rearrangement or mll-partial tandem duplication with dot1l inhibitors. The patients identified as susceptible and the patients (or cells) treated exhibit elevated expression of a hox cluster gene or of a hox cluster-associated gene.
Memorial Sloan-kettering Cancer Center

Bispecific antibodies against cd3epsilon and ror1

A bispecific antibody specifically binding to the two targets human cd3ε (further named also as “cd3”) and the extracellular domain of human ror1 (further named also as “ror1”), characterized in that the bispecific antibody does not internalize in a cell based assay at 37° c. During 2 hrs, using ror1-positive b-cll cells and used at an antibody concentration of 1 nm, whereby not internalize means, that the mean fluorescence intensity (mfi), as detected by flow cytometry, of a bispecific antibody upon binding to ror1-positive primary b-cll cells measured at time 0 is not reduced for more than 50%, preferably not more than 30% when re-measured after a 2 hr-incubation at 37° c.
Engmab Ag

Imidazo-fused heterocycles and uses thereof

Compounds and methods in the fields of chemistry and medicine are disclosed. Some of the disclosed embodiments include compounds, compositions and methods of using imidazole-fused heterocycle amines.
Ligand Pharmaceuticals, Inc.

7-azaindole or 4,7-diazaindole derivatives as ikk epsilon and tbk1 inhibitor and pharmaceutical composition comprising same

Provided are 7-azaindole or 4,7-diazaindole derivatives as an ikkε (i-kappa-b kinase epsilon) and tbk1 (tank-binding kinase 1) inhibitor. The 7-azaindole or 4,7-diazaindole derivative effectively inhibits ikkε and tbk1, and thus is useful not only as an anticancer agent for the treatment of various cancers including colorectal cancer, breast cancer, cns cancer, colon cancer, non-small cell lung cancer, kidney cancer, prostate cancer, ovarian cancer, uterus cancer, stomach cancer, liver cancer, skin cancer, lung cancer, brain cancer, bladder cancer, esophageal cancer, pancreatic cancer, thyroid cancer, head and neck cancer, squamous cell carcinoma, osteosarcoma, b-cell or t-cell lymphoma, acute or chronic leukemia and multiple myeloma, but as a therapeutic agent for chronic inflammation..
Green Cross Corporation

Substituted triazine bmi-1 inhibitors

Amine substituted triazine compounds and forms thereof that inhibit the function and reduce the level of b-cell specific moloney murine leukemia virus integration site 1 (bmi-1) protein and methods for their use to inhibit bmi-1 function and reduce the level of bmi-1 to treat a cancer mediated by bmi-1 are described herein.. .
Ptc Therapeutics, Inc.

Y-90-labeled anti-cd22 antibody (epratuzumab tetraxetan) in refractory/relapsed adult cd22+ b-cell acute lymphoblastic leukemia

The present invention relates to use of 90y-conjugated anti-cd22 antibody for treatment of relapsed/refractory acute lymphoblastic leukemia (all). Preferably the anti-cd22 antibody is epratuzumab tetraxetan.
University Of Nantes

Novel chimeric gene atf7ip-pdgfrb of acute lymphoblastic leukemia

A method for detecting a gene fusion serving as a responsible mutation (driver mutation) for cancer, the method comprising the step of detecting an atf7ip-pdgfrb fusion polynucleotide or a polypeptide encoded thereby, in an isolated sample from a subject.. .

Pyrazole derivatives as tnik, ikke and tbk1 inhibitor and pharmaceutical composition comprising same

Provided is pyrazole derivatives as a tnik (traf2- and nck-interacting kinase), ikkε (i-kappa-b kinase epsilon) and tbk1 (tank-binding kinase 1) inhibitor; the pyrazole derivative according to the present invention effectively inhibits tnik, ikkε and tbk1, and thus is useful not only as an anticancer agent for the treatment of various cancers including colorectal cancer, breast cancer, cns cancer, colon cancer, non-small cell lung cancer, kidney cancer, prostate cancer, ovarian cancer, uterus cancer, stomach cancer, liver cancer, skin cancer, lung cancer, brain cancer, bladder cancer, esophageal cancer, pancreatic cancer, thyroid cancer, head and neck cancer, squamous cell carcinoma, osteosarcoma, b-cell or t-cell lymphoma, acute or chronic leukemia and multiple myeloma, but as a therapeutic agent for chronic inflammation.. .
Green Cross Corporation

Compositions containing ibrutinib

Discussed herein are pharmaceutical compositions containing ibrutinib and processes for preparing them. The compositions may be utilized in the treatment of a variety of conditions including, without limitation, b-cell proliferative disorders such as non-hodgkin lymphoma (diffuse large b cell lymphoma, follicular lymphoma, mantle cell lymphoma or burkitt lymphoma), waldenstrom macroglobulinemia, plasma cell myeloma, chronic lymphocytic leukemia, lymphoma, or leukemia.
Janssen Pharmaceutical Nv

Anti-wt1/hla bi-specific antibody

Disclosed herein is a bi-specific form of a t cell receptor mimic (tcrm) mab with reactivity to human immune effector cell antigen and a wt1 peptide/hla-a epitope. This antibody selectively bound to leukemias and solid tumor cells expressing wt1 and hla-a as well as activated resting human t cells to release interferon-(ifn-γ) and to kill the target cancer cells in vitro.
Eureka Therapeutics, Inc.

Substituted pyridine and pyrazine bmi-1 inhibitors

Amine substituted pyridine and pyrazine compounds and forms thereof that inhibit the function and reduce the level of b-cell specific moloney murine leukemia virus integration site 1 (bmi-1) protein and methods for their use to inhibit bmi-1 function and reduce the level of bmi-1 to treat a cancer mediated by bmi-1 are described herein.. .
Ptc Therapeutics, Inc

Novel cytotoxic agents that preferentially target leukemia inhibitory factor (lif) for the treatment of malignancies and as new contraceptive agents

Described herein are new anti-cancer compounds and methods of using such compounds, acting through a new mechanism of action by simultaneous inhibition of leukemia inhibitory factor (lif) and mdm2.. .
Evestra, Inc.

Compositions and methods for the treatment of acute myeloid leukemias and myelodysplastic syndromes

Provided are compositions and methods for the treatment of hematological conditions, in particular cd99+ acute myelogenous leukemias (aml) and myelodysplastic syndromes (mds), which comprise one or more antibody that (a) binds to the extracellular domain of cd99, (b) ligates aml and/or mds cell-surface expressed cd99, (c) promotes the capping/clustering/aggregation aml and/or mds cell-surface expressed cd99, and (d) induces apoptosis in and consequent cytotoxicity of antibody-ligated cd99+ aml and/or mds cells. Disclosed methods include methods for identifying aml and mds patients that are susceptible to treatment with an anti-cd99 antibody by detecting the elevated expression of cd99 in a tissue sample or cell from an aml or mds patient and for treating an aml and/or mds patient exhibiting elevated cd99 gene and or cell-surface protein expression by administering a composition comprising an anti-cd99 antibody, either alone or in combination with one or more additional component such as a mobilizing agent, a transmigration blocking agent, and an aml and/or mds chemotherapeutic agent, such as daunorubicin, idarubicin, cytarabine, 5-azacytidine, and decitabine..
Memorial Sloan-kettering Cancer Center

Compounds from anisomeles heyneana

The present invention describes use of compounds of formula 1 or 2 or their compositions for the treatment of leukemia and use of compound of formula 1 or its composition for treatment of infections caused due to m. Tuberculosis.
Council Of Scientific & Industrial Research

Pyrrolo pyrimidine derivative

A compound represented by the general formula (1) has a pyridone ring structure introduced into a pyrrolo pyrimidine skeleton, so that the compound has a strong axl inhibitory activity. Consequently, the compound can be used as a therapeutic agent for axl-related diseases including cancers such as acute myeloid leukemia, melanoma, breast cancer, pancreatic cancer, and glioma, kidney diseases, immune system diseases, and circulatory system diseases..
Ono Pharmaceutical Co., Ltd.

Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7)

The present invention provides novel compounds of formula (i), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, lymphoma, melanoma, multiple myeloma, breast cancer, ewing's sarcoma, osteosarcoma, brain cancer, neuroblastoma, lung cancer), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject.
Dana-farber Cancer Institute, Inc.

Heteromaromatic compounds useful for the treatment of prolferative diseases

The present invention provides novel compounds of formula (i) and formula (ii), and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject.
Syros Pharmaceuticals, Inc.

Heteroaromatic compounds useful for the treatment of prolferative diseases

The present invention provides novel compounds of formula (i), and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject.
Dana-farber Cancer Institute, Inc.

Securinine and norsecurinine analogue compounds for the treatment of myeloid disorders

The present application relates to securinine or norsecurinine analogues that, when administered to immature myeloid cells, promote differentiation of these cells to mature cells that do not readily proliferate. Therefore, the agents are useful in the treatment of myeloid disorders including myeloproliferative disorders, acute myeloid leukemia, and autoimmune diseases.
Case Western Reserve University

Kdm1a inhibitors for the treatment of disease

Disclosed herein are new compounds and compositions and their application as pharmaceuticals for the treatment of diseases. Methods of inhibition of kdmia, methods of increasing gamma globin gene expression, and methods to induce differentiation of cancer cells in a human or animal subject are also provided for the treatment of diseases such as acute myelogenous leukemia..
Imago Biosciences Inc.

Use of water soluble platinum complex in preparing drugs for prevention and treatment of cancers

Disclosed in the present invention is the use of a water soluble platinum complex in preparing drugs for the prevention and treatment of tumors, said platinum complex being shown as formula (i). Experiments have demonstrated that the present water soluble platinum complex alone or in combination with other chemotherapeutics is able to treat cancer in mammals, and in particular, humans, said cancers including lung cancer, colon cancer, head and neck cancer, prostate cancer, breast cancer, ovarian cancer, cervical cancer, leukemia, lymphoid cancer, skin cancer, pancreatic cancer, liver cancer, bladder cancer, esophageal cancer, gastric cancer, male genital cancer or bone cancer..
Gudui Biopharma Technology Inc.

Monitoring health and disease status using clonotype profiles

There is a need for improved methods for determining the diagnosis and prognosis of patients with conditions, including autoimmune disease and cancer, especially lymphoid neoplasms, such as lymphomas and leukemias. Provided herein are methods for using dna sequencing to identify personalized, or patient-specific biomarkers in patients with lymphoid neoplasms, autoimmune disease and other conditions.
Adaptive Biotechnologies Corp.

Methods of diagnosing and treating b cell acute lymphoblastic leukemia

Methods for the diagnosis and treatment of b cell acute lymphoblastic leukemia (b-all), based in part on the detection and/or inhibition of focal adhesion kinase (fak), e.g., phosphorylated fak (pfak).. .
Tufts Medical Center

Combination therapy with anti-cd74 and anti-cd20 antibodies provides enhanced toxicity to b-cell diseases

Disclosed are compositions and methods comprising combinations of anti-cd74 and anti-cd20 antibodies or antigen-binding fragments thereof. The antibody combination may also be used with a therapeutic agent that is attached to antibody or fragment thereof or separately administered.
Ibc Pharmaceuticals, Inc.

Methods of treating acute myeloid leukemia with a flt3 mutation

There is provided a method of treating acute myeloid leukemia (aml). The method includes the step of administering to a patient having aml with a fms-like tyrosine kinase 3 (flt3)-mutation a therapeutically effective amount of a cxcr4-antagonistic peptide..
Biolinerx Ltd.

Method for treating acute myeloid leukemia

The present invention relates to the use of bi 6727 or a salt thereof or the hydrate thereof for treating patients suffering from acute myeloid leukemia (aml) comprising the administration of a high dose of bi 6727 according to a specific dosage schedule, optionally in combination with cytarabine.. .
Boehringer Ingelheim International Gmbh



Leukemia topics:
  • Myelogenous
  • Myelogenous Leukemia
  • Proliferative
  • Autoimmune
  • Stem Cells
  • Breast Cancer
  • Rheumatoid Arthritis
  • Myeloid Leukemia
  • Acute Myelogenous Leukemia
  • Lymphocytic
  • Chronic Lymphocytic Leukemia
  • Lymphocytic Leukemia
  • Epigenetic
  • Multiple Myeloma
  • Polyphenol


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Leukemia for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Leukemia with additional patents listed. Browse our RSS directory or Search for other possible listings.


    1.1685

    file did exist - 5443

    2 - 1 - 107